RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

Name: RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
Published: 2006
License: Public Domain

Novartis Pharmaceuticals · 2006

ClinicalTrials.gov · Datasets · License: Public Domain · 2006

Open Source ↗

metastatic renal cell carcinoma, advanced kidney cancer, everolimus, kidney cancer, oral therapy, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

Related documents